-
Product Name
Exatecan Monoclonal Antibody
- Documents
-
Description
Product has been tested in direct ELISA.
-
Tested applications
ELISA
-
Species reactivity
Chemical
-
Isotype
Mouse IgG2b, κ
-
Preparation
Exatecan conjugated with OVA. Protein G affinity purified
-
Clonality
Monoclonal
-
Formulation
PBS(pH7.4), lyophilized. Reconstitution: Adding sterile water, prepare a stock solution of 2.0 mg/ml.
-
Storage instructions
Store at -20℃. Avoid freeze / thaw cycles.
-
Applications
ELISA: 1:5,000-1:20,000
-
Validations
ELISA Binding Assay of Anti-Exatecan Antibody to different proteins.
ELISA analysis of Anti-Exatecan Monoclonal Antibody with Exatecan-OVA, Exatecan-BSA, OVA and BSA. Anti-Exatecan Monoclonal Antibody can bind to Exatecan-BSA or Exatecan-OVA but not carrier proteins.
ELISA Binding Assay of Anti-Exatecan Antibody
Immobilized Exatecan ADC at 2μg/mL (100μL/well) can bind anti-Exatecan mouse monoclonal antibody.
-
Background
Exatecan (Exa) is a very potent inhibitor of topoisomerase I and anticancer agent. It has been intensively studied as a single agent, a large macromolecular conjugate and as the payload component of antigen-dependent antibody–drug conjugates. Exatecan (DX-8951f) is a DNA topoisomerase I (TOP1) inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL).
-
References
- Fontaine SD, Carreras CW, Reid RR, Ashley GW, Santi DV. A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors. Cancer Res Commun. 2023 May 24;3(5):908-916. doi: 10.1158/2767-9764.CRC-22-0517. PMID: 37377899; PMCID: PMC10208276.
- Jo U, Murai Y, Agama KK, Sun Y, Saha LK, Yang X, Arakawa Y, Gayle S, Jones K, Paralkar V, Sundaram RK, Van Doorn J, Vasquez JC, Bindra RS, Choi WS, Pommier Y. TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. Mol Cancer Ther. 2022 Jul 5;21(7):1090-1102. doi: 10.1158/1535-7163.MCT-21-1000. PMID: 35439320; PMCID: PMC9256811.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"